Copy Link Print Information

Ruxolitinib sulfate

(Synonyms: INCB018424 sulfate)
274 Cited Publications
Customer Review

Based on 274 publication(s) in Google Scholar

Ruxolitinib sulfate (INCB018424 sulfate) is the first potent, selective JAK1/2 inhibitor to enter the clinic with IC50s of 3.3 nM/2.8 nM, and has > 130-fold selectivity for JAK1/2 versus JAK3.

For research use only. We do not sell to patients.

  • CAS No.: 1092939-16-6
  • Formula: C17H20N6O4S
  • Molecular Weight:404.44
  • Storage:

    4°C, sealed storage, away from moisture

    * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

  • Ruxolitinib sulfate Chemical Structure
    Ruxolitinib sulfate Chemical Structure
  • Experimental Validation Results for Ruxolitinib sulfate
  • Experimental Validation Results for Ruxolitinib sulfate
  • Experimental Validation Results for Ruxolitinib sulfate
  • Experimental Validation Results for Ruxolitinib sulfate
  • Experimental Validation Results for Ruxolitinib sulfate
  • Experimental Validation Results for Ruxolitinib sulfate
  • Experimental Validation Results for Ruxolitinib sulfate
  • Experimental Validation Results for Ruxolitinib sulfate
  • Experimental Validation Results for Ruxolitinib sulfate
  • Experimental Validation Results for Ruxolitinib sulfate
  • Experimental Validation Results for Ruxolitinib sulfate
  • Experimental Validation Results for Ruxolitinib sulfate
  • Experimental Validation Results for Ruxolitinib sulfate
  • Experimental Validation Results for Ruxolitinib sulfate
  • Experimental Validation Results for Ruxolitinib sulfate
  • Experimental Validation Results for Ruxolitinib sulfate
  • Experimental Validation Results for Ruxolitinib sulfate
  • Experimental Validation Results for Ruxolitinib sulfate
  • Experimental Validation Results for Ruxolitinib sulfate
  • Experimental Validation Results for Ruxolitinib sulfate
CAS No.: 1092939-16-6
Size
Price
Stock
Quantity
Amount: USD 0.00
Please select quantity
or
or

* Please select Quantity before adding items.

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Data Download
Other Forms of Ruxolitinib sulfate:

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
Find Your Local Distributor Your local distributor: Hycultec GmbHHycultec
  • Biological Activity
  • Chemical Information
  • Protocol
  • Purity & Documentation
  • References
  • Help & FAQs
Top Publications Citing

Use of MCE Products

Publications Citing Use of MedChemExpress (MCE) Ruxolitinib sulfate

More
Customer Validation & Images
In Vivo Efficacy StudyIFWBRT-PCRCell Proliferation/Viability Assay
  • In Vivo Efficacy Study
  • RT-PCR
  • Cell Proliferation/Viability Assay
  • RT-PCR
  • RT-PCR
  • WB
  • WB
  • WB
  • RT-PCR
  • IF
  • Cell Proliferation/Viability Assay
  • WB
  • RT-PCR
  • RT-PCR
  • WB
  • WB
  • WB
  • WB
  • WB
  • Cell Proliferation/Viability Assay

All JAK Isoforms

More
Keywords
MOQ
Minimum order quantity
100 mg

Get Quote In-stock

Other size
Get Quote
Please select quantity
Amount: USD 0.00
Sign in to MedChemExpress Sign In
Register
Sign in to MedChemExpress
Register New Account

At least 6 characters

Personalize your experience, you are currently not signed in. For a better experience, please create an online profile, you can:

Obtain points redemption prizes
Check out faster
Add multiple shipping locations
View orders
Assay Types
  • Ruxolitinib sulfate Chemical Structure
    Ruxolitinib sulfate Chemical Structure
    1/16
  • 1/16

    Ruxolitinib sulfate purchased from MedChemExpress. Usage Cited in: N Engl J Med. 2024 May 30;390(20):1873-1884. [Abstract]

    Customer Validation
     Survival rate analysis among groups of the Pilocarpine (300 mg/kg; i.p.)-induced SE model.

  • 1/16

    Ruxolitinib sulfate purchased from MedChemExpress. Usage Cited in: Nature. 2022 Sep;609(7928):785-792. [Abstract]

    Customer Validation
     Huh7 cells are pretreated with DMSO, 5 μM Filgotinib, 5 μM Ruxolitinib or 5 μM IFNα-IFNAR-IN-1 hydrochloride for 1 h and infected with MERS-CoV at a MOI of 1. MERS-CoV N gene copy number is quantified by RT-qPCR.

  • 1/16

    Ruxolitinib sulfate purchased from MedChemExpress. Usage Cited in: Nat Cancer. 2022 Sep;3(9):1071-1087. [Abstract]

    Customer Validation
     Relative cell number of LNCaP/AR cells treated with annotated treatment: 10 µM Enzalutamide (Enz), 5 µM Filgotinib (Filg), 5 µM Ruxolitinib (Ruxo), 1 µM Fludarabine (Flu), 0.2 µM Niclosamide (Nic) and DMSO for 8 days.

  • 1/16

    Ruxolitinib sulfate purchased from MedChemExpress. Usage Cited in: Cell Mol Immunol. 2022 Oct;19(10):1130-1140. [Abstract]

    Customer Validation
     Ruxolitinib (100 mg/kg/day; intraperitoneal injection; 8 weeks) reduces the expression of proinflammatory cytokine genes in the livers of ARE-Del+/− mice. RNA is isolated from the livers of Ruxolitinib-treated mice.

  • 1/16

    Ruxolitinib sulfate purchased from MedChemExpress. Usage Cited in: Cell Mol Immunol. 2022 Oct;19(10):1130-1140. [Abstract]

    Customer Validation
     Levels of IL-6, TNF, and MCP1 production in macrophages isolated from wild-type mice (females/20 weeks) following in vitro treatment with Ruxolitinib are determined utilizing CBA and flow cytometry.

  • 1/16

    Ruxolitinib sulfate purchased from MedChemExpress. Usage Cited in: Cell Mol Immunol. 2022 Oct;19(10):1130-1140. [Abstract]

    Customer Validation
     The expression of phosphorylated (p-) and unphosphorylated STAT1 and STAT6 in macrophages is assessed by western blotting.

  • 1/16

    Ruxolitinib sulfate purchased from MedChemExpress. Usage Cited in: Theranostics. 2022 Oct 3;12(16):7051-7066. [Abstract]

    Customer Validation
     A549 cells are treated with 2.5 µM BVD and 10 µM Ruxolitinib (Rux) separately or in combination for 2 days. Immunoblotting is conducted to determine pSTAT3-Y705.

  • 1/16

    Ruxolitinib sulfate purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2022 May 25;13(5):496. [Abstract]

    Customer Validation
     The xenografts treated with both Trametinib and Ruxolitinib (20 mg/kg; i.p.; every 3 days) show the expression of pSTAT3 and pERK1/2 in xenograft tumors exposed to the indicated treatment. Densitometry analyses of pSTAT3 and pERK1/2 expression normalized to STAT3 and ERK1/2 expression, respectively.

  • 1/16

    Ruxolitinib sulfate purchased from MedChemExpress. Usage Cited in: Proc Natl Acad Sci U S A. 2022 Apr 12;119(15):e2122512119. [Abstract]

    Customer Validation
     The induction of MIS target genes Id2, Id3, Smad6, and Igfbp5 was recapitulated as measured by qPCR following a 48 h incubation of ex vivo cultured ovaries from PND2 rat with 1 μM candidate MISR2 agonists Gandotinib, SP600125m, CYC-116, Ruxolitinib.

  • 1/16

    Ruxolitinib sulfate purchased from MedChemExpress. Usage Cited in: Proc Natl Acad Sci U S A. 2022 Apr 12;119(15):e2122512119. [Abstract]

    Customer Validation
     Representative DDX4 immunofluorescence following 48 h incubation of ovaries from PND2 mice cultured ex vivo with 1 μM candidate MISR2 agonists Gandotinib, SP600125, CYC-116, Ruxolitinib.

  • 1/16

    Ruxolitinib sulfate purchased from MedChemExpress. Usage Cited in: J Hematol Oncol. 2021 Jun 24;14(1):97. [Abstract]

    Customer Validation
     Growth curves for DND-41, RPMI-8402 and LOUCY T-ALL cell lines. Growth medium is supplemented with DMSO, MRK-560 100 nM, Ruxolitinib 1 µM or both compounds.

  • 1/16

    Ruxolitinib sulfate purchased from MedChemExpress. Usage Cited in: Cancer Commun (Lond). 2021 Dec;41(12):1354-1372. [Abstract]

    Customer Validation
     The MAGE‐C3 overexpressing KYSE30 cells are treated with Ruxolitinib (2 μM, for 20 h.) and probed for STAT1 expression pSTAT1Tyr701. The pSTAT1Tyr701 expression levels are almost unchanged when exposure to Ruxolitinib in presence with IFN‐γ.

  • 1/16

    Ruxolitinib sulfate purchased from MedChemExpress. Usage Cited in: Nat Commun. 2021 Aug 13;12(1):4917. [Abstract]

    Customer Validation
     The A3A mRNA level is monitored in MCF10A cells 16 h after treatment with 3p-hpRNA and JAK inhibitors (JAKi #1: 2 μM Pacritinib, JAKi #2: 2 μM Ruxolitinib).

  • 1/16

    Ruxolitinib sulfate purchased from MedChemExpress. Usage Cited in: Cell Rep. 2020 Sep 15;32(11):108158. [Abstract]

    Customer Validation
     Cxcl10 and Ccl5 mRNA levels are analyzed in TNF-α (100 ng/mL)-stimulated BMDMs for 6 h, which are pretreated with notopterol (10 mM) in the presence or absence of ruxolitinib (10 μM) or SD1029 (10 μM) for 3 h.

  • 1/16

    Ruxolitinib sulfate purchased from MedChemExpress. Usage Cited in: Nat Med. 2018 Aug;24(8):1143-1150. [Abstract]

    Customer Validation
     Immunoblot of pSTAT1, STAT1 and β-actin levels in H69AR cells±200 ng/mL IFNg 10 min pulse followed by 24 h chase in media with DMSO, Ruxolitinib (100 nM) or MRT67307 (1 µM).

  • 1/16

    Ruxolitinib sulfate purchased from MedChemExpress. Usage Cited in: Cancer Discov. 2018 May;8(5):616-631. [Abstract]

    Customer Validation
     Analysis of PIM1 RNA and protein expression in HOXA9 positive patient derived xenograft (PDX) samples ex vivo after 1 μM Ruxolitinib over 6 hours.

  • 1/16

    Ruxolitinib sulfate purchased from MedChemExpress. Usage Cited in: Clin Cancer Res. 2018 Apr 15;24(8):1917-1931. [Abstract]

    Customer Validation
     Jak2 is inhibited by lentiviral expression of Jak2 shRNA or control shRNA in CWR22Pc and CWR22Rv1 cells. Alternatively, cells are treated with Jak2 inhibitors AZD1480 (0.8 μM) and Ruxolitinib (0.4 μM) (72 h), followed by Western blot analysis of Jak2 and active Stat5a/b.

  • 1/16

    Ruxolitinib sulfate purchased from MedChemExpress. Usage Cited in: JCI Insight. 2018 Sep 6;3(17):e120750. [Abstract]

    Customer Validation
     A431 cells are then treated in full growth media with vehicle, CSA (50 ng/mL), Ruxolitinib (20 μM), or both Ruxolitinib and CSA for 36 hours.

  • 1/16

    Ruxolitinib sulfate purchased from MedChemExpress. Usage Cited in: J Biol Chem. 2015 Nov 27;290(48):29022-34. [Abstract]

    Customer Validation
     106 autonomous Ba/F3 cells stably transduced with ALL-associated JAK3 mutant V674A or double mutant L857P/Y100A are treated with increasing concentration of Ruxolitinib (0–2 μM). Two hours after treatment, the cells are lysed and subjected to Western blot analysis. Phosphorylation of STAT5, JAK3, and JAK1 is detected using specific anti-pY694 STAT5, anti-pY980/81 JAK3, and anti-pY1034/35 JAK1 antibodies. Membranes are reprobed with anti-STAT5, anti-JAK3, anti-JAK1, and anti-β-actin an

  • 1/16

    Ruxolitinib sulfate purchased from MedChemExpress. Usage Cited in: Blood. 2013 Nov 21;122(22):3628-31. [Abstract]

    Customer Validation
     Ruxolitinib decreases spleen weight. Mice are sacrificed on day 21 or 24 to evaluate spleen size.

  • Ruxolitinib sulfate